Skip to main content
. Author manuscript; available in PMC: 2020 Mar 4.
Published in final edited form as: Nat Rev Neurol. 2019 Jul 31;15(9):501–518. doi: 10.1038/s41582-019-0228-7

Figure 2: APOE genotype and amyloid positivity.

Figure 2:

Estimated probabilities of amyloid positivity according to apolipoprotein E (APOE) genotype, plotted against age in cognitively healthy individuals and individuals with mild cognitive impairment (MCI). Shaded areas represent 95% CIs. In both groups, APOE*ε4/ε4 individuals are more likely to be positive for amyloid pathology than individuals with any other genotype, whereas APOE*ε2/ε2 individuals have the lowest probability of amyloid positivity. Also note that APOE*ε4 is a strong driver of Aβ positivity irrespective of the presence of APOE*ε2 or APOE*ε3. Data for APOE*ε2/ε2 individuals are not shown in the right panel owing to a small sample size. Adapted with permission from REF.85, American Medical Association.